reports
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Result...
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday,...
TELA Bio to Announce First Quarter 2025 Financial Results
TELA Bio to Announce First Quarter 2025 Financial Results MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors...
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMR...
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today reported that its sub-licensee in Canada, Kye Pharmaceuticals, Inc. (Kye), has announced that Health Canada has accepted the Ne...
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRGS PROGRESS SOFTWARE CORPORATION
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
MNRO MONRO INC
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
SAFE SAFEHOLD INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
ATXS ASTRIA THERAPEUTICS INC
AVTE AEROVATE THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
- Jay Kornreich
- Richard Anderson
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® P...
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic...
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for O...
Catalyst Pharmaceuticals Inc: 2 directors
Two Directors at Catalyst Pharmaceuticals Inc sold after exercising options/sold 93,398 shares at between 22.890USD and 22.976USD. The significance rating of the trade was 91/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trad...
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Gl...
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 27th Annual Global Hea...
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Resul...
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference ...
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2...
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE® and Continued Market Adoption of AGAMREE® Pursuing Strategic Investments to Expand Market Presence and Accelerate Growth Full Year 2025 Total Revenues Expec...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 7,200 shares of its common stock to thirteen newly-hired employees, with a grant date of February 19, 2025 (the "Grant Date"). The restricted stock units were grante...
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 F...
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 The Company will Host a Conference Call and Webcast on February 27, 2025, at 8:30 AM ET CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2024 financial resu...
- Wedbush Research
XNCR XENCOR INC.
WEN WENDY'S COMPANY
WDC WESTERN DIGITAL CORPORATION
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
QLYS QUALYS INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MCD MCDONALD'S CORPORATION
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EBAY EBAY INC.
DENN DENNY'S CORPORATION
CXW CORECIVIC INC.
CRM SALESFORCE.COM INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
EPRT ESSENTIAL PROPERTIES REALTY TRUST
SAFE SAFEHOLD INC.
PINS PINTEREST INC. CLASS A
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
IGMS IGM BIOSCIENCES
SMCI SUPER MICRO COMPUTER
ORIC INC.
FUBO ORIC PHARMACEUTICALS
DASH FUBOTV
ABNB DOORDASH
VRDN AIRBNB INC. CLASS A
RBLX VIRIDIAN THERAPEUTICS INC
STX ROBLOX
TTD SEAGATE TECHNOLOGY HLDGS PLC
GFS THE TRADE DESK
NTST INC.
ARTV GLOBALFOUNDRIES INC
BROS NETSTREIT CORP
DNTH ARTIVA BIOTHERAPEUTICS INC
DUTCH BROS INC
DIANTHUS THERAPEUTICS INC
- Jay Kornreich
- Richard Anderson
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 4,000 shares of its common stock to seven newly-hired employees, with a grant date of January 21, 2025 (the "Grant Date"). The restricted stock units were granted pu...
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 L...
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Mid-Cap Companies for the year 2025. Catalyst has ranked an impressive fifth out of 100 companies on the list. Last year Catalyst was ranked fourth in Forbes’ list of America’s Most Successful Small-Cap Companies, with this year’s ranking recognizing the comp...
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched F...
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lambert-Eaton...
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifamprid...
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. (...
- Wedbush Research
DEI DOUGLAS EMMETT INC
WFC WELLS FARGO & COMPANY
WDC WESTERN DIGITAL CORPORATION
UMH UMH PROPERTIES INC.
UDR UDR INC.
TRNO TERRENO REALTY CORPORATION
STAG STAG INDUSTRIAL INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBRA SABRA HEALTH CARE REIT INC.
RHP RYMAN HOSPITALITY PROPERTIES INC.
REXR REXFORD INDUSTRIAL REALTY INC.
PEGA PEGASYSTEMS INC.
PEB PEBBLEBROOK HOTEL TRUST
OHI OMEGA HEALTHCARE INVESTORS INC.
OFC CORPORATE OFFICE PROPERTIES TRUST
O REALTY INCOME CORPORATION
NRZ NEW RESIDENTIAL INVESTMENT CORP.
NHI NATIONAL HEALTH INVESTORS INC.
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
LTC LTC PROPERTIES INC.
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GLPI GAMING AND LEISURE PROPERTIES INC.
GERN GERON CORP.
FR FIRST INDUSTRIAL REALTY TRUST INC.
ESS ESSEX PROPERTY TRUST INC.
EQR EQUITY RESIDENTIAL
EGP EASTGROUP PROPERTIES INC.
CTRE CARETRUST REIT INC
CRM SALESFORCE.COM INC.
CPT CAMDEN PROPERTY TRUST
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CAKE CHEESECAKE FACTORY INCORPORATED
BXP BOSTON PROPERTIES INC.
AVB AVALONBAY COMMUNITIES INC.
APLE APPLE HOSPITALITY REIT INC
HST HOST HOTELS & RESORTS INC.
CMA COMERICA INCORPORATED
PK PARK HOTELS & RESORTS INC.
PLYM PLYMOUTH INDUSTRIAL REIT INC.
VTR VENTAS INC.
VICI VICI PROPERTIES INC
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
EPRT ESSENTIAL PROPERTIES REALTY TRUST
SAFE SAFEHOLD INC.
PEAK HEALTHPEAK PROPERTIES INC.
PLTR PALANTIR TECHNOLOGIES
WOOF PETCO HEALTH AND WELLNESS
AIRC APARTMENT INCOME REIT
CSR CENTERSPACE
SNOW SNOWFLAKE INC. CLASS A
RBLX ROBLOX
NTST NETSTREIT CORP
HR HEALTHCARE TRUST OF AMERICA INC.
EWTX EDGEWISE THERAPEUTICS INC
BNL BROADSTONE NET LEASE INC
WAL-US WESTERN ALLIANCE BANCORPORATION
ESTC-US ELASTIC INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.